Curis (NASDAQ:CRIS) Raised to “Hold” at Zacks Research

Curis (NASDAQ:CRIS) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Other analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a research note on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $340.00 target price on shares of Curis in a research note on Friday, March 20th. Finally, Wall Street Zen upgraded Curis to a “hold” rating in a research note on Saturday, March 28th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $340.00.

Curis Stock Down 2.1%

Shares of NASDAQ CRIS opened at $4.65 on Monday. Curis has a fifty-two week low of $3.61 and a fifty-two week high of $39.00. The business has a 50 day moving average price of $8.67 and a two-hundred day moving average price of $14.10. The firm has a market cap of $9.07 million, a PE ratio of -0.20 and a beta of 3.08.

Curis (NASDAQ:CRIS) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($25.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.53) by ($18.47). On average, analysts anticipate that Curis will post -25.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CRIS. Maverick Capital Ltd. boosted its holdings in shares of Curis by 7.8% in the 2nd quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after buying an additional 49,554 shares during the period. Squarepoint Ops LLC lifted its holdings in Curis by 17.9% in the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 8,973 shares during the last quarter. Armistice Capital LLC lifted its holdings in Curis by 8.7% in the third quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock worth $1,624,000 after acquiring an additional 78,265 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Curis by 2,883,237.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock valued at $228,000 after acquiring an additional 230,659 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after acquiring an additional 65,404 shares during the period. 29.97% of the stock is currently owned by institutional investors.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.